ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine BNT162b2 (Pfizer)
The product page has been revised as follows:

- **Indications:**
  - Content has been revised to indicate the vaccine is for individuals 12 years of age and older.

- **Contraindications:**
  - Content has been added to indicate that individuals who had an anaphylactic reaction to a previous dose of these vaccines should be offered an adenovirus vector COVID-19 vaccine and observed for at least 30 minutes after immunization.

- **Adverse Events:**
  - Content has been added regarding Myocarditis and Pericarditis following receipt of mRNA COVID-19 vaccines.

Please remove page numbers: 1-5 dated June 3, 2021
Please add new page numbers: 1-5 dated June 18, 2021

COVID-19 mRNA Vaccine mRNA-1273 (Moderna)
The product page has been revised as follows:

- **Indications:**
  - Content has been revised to indicate the vaccine is for individuals 18 years of age and older.

- **Storage and Handling:**
  - Room temperature parameters have been revised to indicate vaccine storage time of 24 hours is cumulative.
• **Contraindications:**
  o Content has been added to indicate that individuals who had an anaphylactic reaction to a previous dose of these vaccines should be offered an adenovirus vector COVID-19 vaccine and observed for a least 30 minutes after immunization.

• **Adverse Events:**
  o Content has been added regarding Myocarditis and Pericarditis following receipt of mRNA COVID-19 vaccines.

**COVID-19 Vaccine (ChAdOx1-S [recombinant]) (AstraZeneca/Verity Pharmaceuticals)**

The product page has been revised as follows:

• **Indications:**
  o The content indicating that NACI recommends these vaccines only be offered to individuals 30 year of age and older has been deleted from Footnote B.

• **Contraindications:**
  o Content has been added to indicate that individuals who had an anaphylactic reaction to a previous dose of these vaccines should be offered an mRNA COVID-19 vaccine and observed for a least 30 minutes after immunization.
  o A history of capillary leak syndrome has been added as a contraindication to the AstraZeneca/COVISHIELD vaccines.

• **Adverse Events:**
  o The rate of Thrombosis with Thrombocytopenia (TTS) following first dose has been updated to 1 in 50,000.
  o A description of capillary leak syndrome and observed rates following receipt of AstraZeneca vaccine has been added.

**COVID-19 Vaccine Screening Checklist**

The screening checklist has been updated as follows:

• A question has been added under Contraindications related to a history of capillary leak syndrome.
The COVID-19 Vaccines HealthLinkBC File is being updated and will be posted shortly.

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health, Population & Public Health Division:
Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division

Deputy Provincial Health Officer
Dr. Martin Lavoie